The Invisible Conductor: A Detective Story About Hormones

Three in the morning in the emergency department. An elderly woman is wheeled in, confused, her skin dry as paper, blood glucose spiking past 700. In the next bed, a young man breathes deep and fast, his breath carrying a whiff of rotten apples, the blood gas report reading pH 7.1. In the bed beyond that, a mother three weeks postpartum says weakly that "my milk just won't come in," her blood pressure almost too low to register.

On the surface these three people have nothing in common. But if you speak the language of endocrinology, you will see they are all telling the same story — some invisible conductor has lost control. Hormones never shout; through negative feedback, through receptors, through one exquisite switch after another, they quietly decide how fat or thin we are, how hot or cold we feel, whether we stay conscious or slip into coma. The endocrinology section of the licensing exam is fascinating (and also terrifying) precisely because it never asks you to memorize by rote — it asks you to reason like a detective: see one clue, and deduce the entire causal chain.

Act I of this issue starts from the causal threads behind the deposits and colors on a pathology slide, walks through the thyroid — the body's accelerator pedal — through two starkly different diabetic emergencies, into the small universe of glands hidden in the sella turcica, and finally settles on the chronic storm called "insulin resistance" behind body weight and blood lipids. By the end, you will find every test point strung along the same chain of reasoning.

At first glance, the endocrine pathology questions on the licensing exam simply ask you to recognize a color, a deposit, a cell type on a slide, and match it to a diagnosis. But the real skill is not rote-memorizing these pairings — it is asking each clue "why does it look like this?" Once you understand that lipofuscin is a pigment accumulated over years of cellular metabolism, that amyloid is misfolded protein packed into the islets, and that insulitis is the shrapnel left behind when an immune army storms the gland, the line running from slide to diagnosis will connect itself the moment you understand it — no memorization required. The table below is not a "matching mind map" meant to be memorized up front; it is a quick-reference summary to glance back at only after you have read the whole section and thought each causal thread all the way through.

The Adrenal Cortex: A Power Game Between "Boss" and "Sidekick"

To understand every pathological change in the adrenal cortex, remember just one sentence: cortisol is the "boss," ACTH is the "sidekick."

This logic leads directly to the exam's favorite topic — sorting the causes of Cushing syndrome. The trick is to use ACTH level as the axis: the single most common cause overall is actually exogenous (iatrogenic) steroids; among endogenous causes, the most common is Cushing "disease" (a pituitary ACTH-secreting adenoma), which is ACTH-dependent (ACTH↑, bilateral hyperplasia); and among ACTH-independent causes (ACTH suppressed), the most common is adrenal cortical adenoma. As for ectopic ACTH (as in small cell lung cancer), this too is ACTH-dependent, typically with markedly elevated ACTH, hypokalemia, and skin hyperpigmentation.

Disaster from the Core: Waterhouse-Friderichsen Syndrome

The causal chain of WFS is clean and direct: meningococcal (Neisseria meningitidis) sepsis → endotoxin triggers DIC → adrenal vessels thrombose and undergo necrosis → massive hemorrhage → acute adrenal insufficiency (adrenal crisis). Clinically this presents as sudden-onset shock, purpura, hypotension, hypoglycemia, hyponatremia, and hyperkalemia.

The test point hides in the direction of hemorrhage. Bleeding begins in the medulla and spreads outward to the cortex (inside-out), because the medulla's sinusoidal vessels are the most fragile during DIC and rupture first. Exam questions love reversing the direction to "cortex→medulla" as a trap. The memory hook is simple: disaster starts at the core — the medulla (the center) bleeds first.

Pheochromocytoma: Don't Assign S100 to the Wrong Cell

Pheochromocytoma arises from chromaffin cells of the adrenal medulla (of neural crest origin) and secretes catecholamines. Histologically the cells arrange into elegant Zellballen (cell nests) made of two cell types — and this is exactly where the exam takes aim.

Clinically, the first-choice biochemical test is plasma or 24-hour urinary metanephrines (the highest sensitivity), not cortisol. There is an iron rule for treatment: give an α-blocker (phenoxybenzamine) before surgery, then a β-blocker. Reversing the order leaves the α-receptors unopposed and triggers a hypertensive crisis.

As for the classic "rule of 10s" (10% bilateral, 10% extra-adrenal = paraganglioma, 10% malignant, 10% in children, 10% familial), it remains a frequently tested mnemonic but is now outdated. The 2026 view: with genetic testing now widespread, roughly 30–40% turn out to be hereditary (far higher than the old 10%), linked to MEN2 (RET), VHL, NF1, SDHx; every patient is therefore recommended for genetic testing referral. Malignancy is not determined by histology but by the presence or absence of metastasis (patients with SDHB mutations carry the highest malignant risk).

Pituitary and Islets: Two Trailers

Anterior pituitary adenoma is the most common cause of pituitary hyperfunction (do not mistake this for hypothalamic disease), and among these, the most common functional type is prolactinoma (hyperprolactinemia → galactorrhea, menstrual irregularity, decreased libido). Once an adenoma exceeds 1 cm and becomes a macroadenoma, it can press upward on the optic chiasm and cause bitemporal hemianopsia, and it is prone to intratumoral hemorrhage and necrosis — this is pituitary apoplexy: sudden severe headache, vision loss, and acute hypopituitarism, a genuine endocrine emergency. Another exam favorite is craniopharyngioma: a suprasellar cystic mass containing keratinized squamous epithelium and cholesterol crystals ("motor-oil"-like cyst fluid), often calcified, arising from Rathke pouch remnants — and not a functional adenoma.

The pathology of the two types of diabetes in the islets forms a beautifully clean contrast: type 1 is the immune system "attacking" the islets (insulitis — lymphocytic infiltration, β-cell destruction, positive GAD65/ICA/IA-2 antibodies); type 2 is protein "clogging" the islets (amyloid deposition, composed of IAPP/amylin, seen in roughly 90% of patients).

If the adrenal gland is the crisis-response center, the thyroid is the body's accelerator pedal: press it deep (hyperthyroidism) and everything speeds up — weight loss, heat intolerance; ease off (hypothyroidism) and everything slows down — weight gain, cold intolerance. Understand this metaphor and you can deduce half the symptoms yourself.

From Synthesis to Action: Understand the Physiology First, and the Symptoms Follow

Two Axes Are All You Need to Sort It Out: TSH + FT4

The core logic of interpretation: TSH is the pituitary's "feedback report" on thyroid hormone. In primary thyroid disease, TSH and FT4 must move in opposite directions; whereas in central (pituitary) disease, the two move in the same direction, or TSH is inappropriately normal — this is exactly why looking at TSH alone will miss a central lesion.

Do not mix up the two antibodies: Hashimoto's = TPO (it "grinds down" the thyroid → hypothyroidism); Graves' = TRAb (stimulates the receptor → hyperthyroidism). Graves' ophthalmopathy results from TRAb attacking the retro-orbital fibroblasts and extraocular muscles, and it has no direct correlation with the level of thyroid function — even with thyroid function well controlled, the eye disease can still progress, and smoking makes it worse. The related pretibial myxedema is a non-pitting, orange-peel-like change; this "non-pitting" detail is a frequently tested trap.

Nodules and Cancer: Which Marker, Which Metastatic Route

To evaluate a thyroid nodule, first draw TSH and get an ultrasound; if TSH is low (possibly a hot nodule), get a radionuclide scan; if TSH is normal or high with suspicious features, do FNAC. Keep this firmly in mind: FNAC is the gold standard for the preoperative distinction of benign from malignant (not ultrasound or scintigraphy), and it is especially good at diagnosing papillary carcinoma; but follicular carcinoma is hard to confirm by FNA, because the distinction between benign and malignant lies in vascular or capsular invasion, which requires surgical pathology.

The postoperative surveillance marker is also an easy point: for well-differentiated (papillary/follicular) cancer after total resection, follow thyroglobulin (Tg) (not AFP); for medullary carcinoma, follow calcitonin + CEA. Among risk factors, the most important is a history of head-and-neck radiation exposure, followed by male sex, age <20 or >45 years, a fixed firm nodule, and cervical lymphadenopathy.

Thyroid Storm: An "All-of-the-Above" Combination Worth Free Points

There are two fatal traps here. First, the iodine solution must be given about 1 hour after the ATD — give it first, and iodine instead becomes the raw material for thyroid hormone synthesis, pouring oil on the fire. Second, amiodarone is contraindicated in storm complicated by atrial fibrillation, because it carries a large iodine load. Incidentally, amiodarone's fraught relationship with the thyroid is itself a test point: it can cause Type 1 AIT (iodine-induced overproduction in a pre-existing nodule or Graves' disease, with normal or increased radioactive iodine uptake and increased color Doppler flow, treated with a thionamide/methimazole) and Type 2 AIT (a destructive thyroiditis in which the drug directly damages the follicles, with low radioactive iodine uptake and decreased flow, treated with a glucocorticoid), and it can also cause hypothyroidism through failure to escape the Wolff-Chaikoff effect.

Under ordinary (non-emergency) treatment, hyperthyroidism has three paths: antithyroid drugs (ATD) — methimazole is first-choice (once daily), with PTU reserved for the first trimester of pregnancy and for storm; radioactive iodine (RAI, ¹³¹I) — definitive treatment, contraindicated in pregnancy and lactation, may worsen the eye disease; surgery — for a large goiter, compression, suspected malignancy, or when a pregnant patient cannot take medication. Watch for this trap: "stereotactic radiotherapy" is used for brain lesions and is not a treatment for hyperthyroidism; the "radiotherapy" of hyperthyroidism refers to RAI. One more life-saving reminder: if a patient on an ATD develops fever plus sore throat, stop the drug immediately and check WBC/ANC to rule out agranulocytosis — never write it off as a common cold.

As for the emergencies at either extreme: myxedema coma is severe hypothyroidism with hypothermia and altered consciousness, treated with IV levothyroxine plus hydrocortisone (the steroid is given first to prevent adrenal crisis). During pregnancy, thyroid hormone requirements rise by roughly 25–50%, and patients with pre-existing hypothyroidism must have their levothyroxine dose increased.

First, Get the Homeostasis Straight

Glucose homeostasis relies on two mutually antagonistic hormones from the same islet. β cells secrete insulin (lowers glucose: promotes uptake, synthesizes glycogen and fat, suppresses gluconeogenesis); α cells secrete glucagon (raises glucose: promotes glycogenolysis and gluconeogenesis). Remember one point that is often tested in reverse: glucagon is a glucose-raising hormone, a rescue drug for hypoglycemia, not a glucose-lowering drug.

A few numeric thresholds: the normal lower limit of fasting plasma glucose is approximately 70 mg/dL (not 50). Hypoglycemia is diagnosed using the Whipple triad — low blood glucose (<70, with biochemistry often defining it strictly as <55), symptoms of hypoglycemia, and relief after glucose administration. The thresholds for diagnosing diabetes are: fasting ≥126, 2-hour OGTT ≥200, random ≥200 plus symptoms, or HbA1c ≥6.5%.

The core contrast between the types lies in etiology: T1DM is β-cell destruction by the immune system (absolute deficiency); T2DM is insulin resistance plus relative deficiency.

A trap that often gets slipped in: T2DM that requires insulin is still T2DM — it does not "convert" into T1DM. Whether insulin is used is a matter of treatment need, unrelated to the etiological classification.

Mechanism Decides Everything: Ketones vs. Osmolarity

The details of sodium and potassium are hotly contested ground. Sodium: for every 100 mg/dL that glucose is elevated, the measured Na⁺ is diluted and underestimated by roughly 1.6–2.4 mEq/L; after correction it often becomes hypernatremia, which is what actually reflects the true degree of dehydration — so the measured sodium in HHS is not a reliable indicator of dehydration. Potassium is even more of a must-know: insulin deficiency plus acidosis drives K⁺ out of the cells, so the drawn K⁺ is normal or even elevated, while the total body potassium is actually deficient; the moment insulin is given, K⁺ rushes back into the cells, causing hypokalemia, which can trigger fatal arrhythmias.

Order of Management: Fluids First, Check Potassium, Then Insulin

1. Begin with large-volume IV fluids (0.9% NS) to improve perfusion and blood pressure.

2. Decide based on potassium: K⁺ <3.3 → replace potassium first, hold insulin; K⁺ 3.3–5.2 → add potassium to the fluids and start insulin; K⁺ >5.2 → hold potassium for now.

3. Low-dose continuous IV insulin at 0.1 U/kg/hr (may start with a 0.1 U/kg IV bolus); the key is continuous low-dose IV infusion, and oral glucose-lowering drugs must never be substituted.

4. Once glucose falls to about 200 mg/dL → add glucose to the infusion and continue insulin until the ketoacidosis clears (anion gap returns to normal).

5. Monitor glucose, electrolytes, pH, and anion gap throughout.

There is also one drug that is not routinely given: bicarbonate is not routinely replaced in DKA, and is only cautiously considered in extremely severe acidosis with pH < 6.9. Giving it too early can instead cause paradoxical CNS acidification, worsen hypokalemia, and impair tissue oxygenation (a leftward shift of the oxygen dissociation curve).

Medications, Complications, and Hypoglycemia

The choice of glucose-lowering drug depends on mechanism, hypoglycemia risk, weight effect, and contraindications.

Several high-frequency traps: metformin very rarely causes hypoglycemia, but long-term use can cause B12 deficiency, and it should be held for about 48 hours before and after iodinated contrast studies to prevent lactic acidosis (stable heart failure with adequate eGFR is not a contraindication). Weight loss relies on SGLT-2i and GLP-1 RA, whereas DPP-4i is weight-neutral — do not mistake it for a weight-loss drug. Thiazides raise blood glucose but do not cause hypoglycemia — do not reverse this direction.

As for chronic complications, remember the early microvascular marker: early diabetic nephropathy presents as microalbuminuria (30–300 mg/day), at which point creatinine is still normal; ACEI/ARB is first-choice for renal protection — do not wait for creatinine to rise before screening. Retinopathy is assessed by fundoscopy, neuropathy is screened with the 10 g monofilament / vibration sense. Macrovascular control is more aggressive than in the general population: blood pressure <130/80, LDL-C <70 (<55 in very-high-risk patients). When osteomyelitis is suspected in a diabetic foot, a superficial wound swab often does not match the deep tissue — bone biopsy is the gold standard for both diagnosis and antibiotic selection.

Glycemic targets must be individualized: for the general adult, HbA1c <7.0%; for the young, with short disease duration and no hypoglycemia risk, <6.5% is acceptable; but for the elderly (>80), those with multiple comorbidities, or a short life expectancy, the target should be relaxed to <8.0–8.5% — do not force a target of <6.5% and risk hypoglycemia.

Finally, hypoglycemia itself. The most common cause of fasting hypoglycemia is a glucose-lowering drug (a sulfonylurea or insulin), not an insulinoma. To distinguish them, check C-peptide: an insulinoma is endogenous, so insulin↑ + C-peptide↑; if exogenous insulin has been injected, C-peptide is instead low. Management: if the patient is alert, give 15 g of oral glucose (recheck in 15 minutes); if unconscious, give IV D50 or intramuscular glucagon.

There is also one special case that is easy to overlook — Pompe disease (GSD II): a deficiency of acid α-glucosidase (GAA) causes lysosomal glycogen accumulation, and the infantile form presents with hypertrophic cardiomyopathy plus hypotonia; Taiwan has already incorporated this into newborn screening, and enzyme replacement therapy (ERT) is available — early treatment improves prognosis.

The pituitary gland is only pea-sized, yet it is an entire small universe. To master it, grasp one framework first: the anterior lobe is the "gland" — it synthesizes six hormones itself (GH, PRL, TSH, ACTH, FSH, LH), regulated by hypothalamic portal hormones; the posterior lobe is merely "storage" — it synthesizes nothing, only releasing ADH and oxytocin that the hypothalamic SON/PVN nuclei have already made.

Hidden here is one unique special case: PRL is the only anterior pituitary hormone under primarily "inhibitory" control — hypothalamic dopamine keeps its foot on the brake continuously. So when the pituitary stalk is compressed (the stalk effect) and dopamine cannot get through, PRL rises mildly, which explains why "a non-prolactinoma can also cause high PRL." This is also why prolactinoma is the only pituitary adenoma for which medication is first-choice: dopamine agonists (cabergoline is first-choice, bromocriptine) can both lower PRL and shrink the tumor, and surgery is reserved only for those who cannot tolerate or do not respond to medication, or who develop pituitary apoplexy — exactly the opposite of the "surgery-first" approach for other secretory adenomas. There is also a differential trap: a giant prolactinoma can cause the immunoassay to falsely underestimate PRL through the hook effect, and when suspicion is high, the serum should be diluted and retested.

Acromegaly: Why Not Just Measure GH Directly

Back to the opening question — why not just measure GH directly? Because GH is secreted in pulses, so a single blood draw carries very little meaning; whereas IGF-1 has a long half-life and a stable concentration, reflecting the "integrated total" of GH over 24 hours, so IGF-1 is first-choice for screening.

`

Suspected → ① IGF-1 (screening, first-choice)

↓ elevated

② OGTT suppression test: oral 75 g glucose

In a normal person GH is suppressed to <1 μg/L (with high-sensitivity assays, a nadir <0.4 μg/L is often used as normal)

→ in acromegaly, GH "is not suppressed" = confirms the diagnosis

↓

③ Pituitary MRI to localize the tumor

`

Transsphenoidal surgery is first-choice treatment (cure rate >90% for microadenomas); for postoperative residual disease, a somatostatin analog (octreotide, lanreotide) is the most effective at lowering GH/IGF-1; pegvisomant is a GH-receptor antagonist that lowers peripheral IGF-1 only and does not shrink the tumor; cabergoline is weaker but can be used when PRL is also elevated; radiotherapy takes years to take effect and is reserved for those who fail both surgery and medication.

The Three Brothers of Polyuria: Water Deprivation Can't Tell Them Apart — ADH Replacement Reveals the Truth

The key is: water deprivation cannot distinguish CDI from NDI (neither can concentrate urine), and ADH replacement is what reveals the truth — the one that rises is central, the one that does not is nephrogenic. Common causes of CDI include trauma/postoperative, skull-base fracture, tumor (craniopharyngioma, metastasis), lymphocytic hypophysitis, and idiopathic; the most common drug cause of NDI is lithium, with others including hypercalcemia, hypokalemia, and congenital V2/AQP2 defects.

Do not confuse this with SIADH — that is the opposite disease: excess ADH → water retention → euvolemic hyponatremia, concentrated urine, high urine sodium. Also, lymphocytic hypophysitis favors pregnant or postpartum women; MRI shows gland enlargement (a mass effect), not an empty sella, often combined with CDI plus anterior lobe hypofunction.

Sheehan Syndrome: The Order Hormones Are Lost Is the Order They Appear Clinically

The order in which anterior pituitary hormones are lost is almost exactly the order clinical features appear:

There is an iron rule for acute decompensation: replace glucocorticoid (hydrocortisone) before thyroid hormone — reversing the order can precipitate adrenal crisis (the same logic as the management of myxedema coma).

Hypogonadism and MEN: Two Mental Shortcuts to Finish

Hypogonadism needs just one mental shortcut: look at FSH/LH — high = the gonad itself has failed (primary); low or inappropriately normal = the upstream source has failed (secondary).

The most frequently tested "elevated FSH" scenario is postmenopause — ovarian failure, loss of negative feedback, FSH persistently high, estradiol low. Do not remember this backwards as "FSH falls after menopause."

As for MEN, it's enough to remember the combination and the gene:

Keep this firmly in mind: medullary thyroid carcinoma (MTC) and pheochromocytoma belong to MEN 2 (RET gene), not MEN 1; carriers of a RET mutation in MEN 2 can undergo prophylactic total thyroidectomy. Meanwhile, the hyperparathyroidism of MEN 1 is usually multigland hyperplasia, not a single adenoma.

Metabolic Syndrome: 3 of 5, and Why LDL Is Deliberately Left Out

The Taiwan Ministry of Health and Welfare standard confirms the diagnosis when at least 3 of 5 criteria are met:

The most frequently tested question: why doesn't this include LDL? Because the core of metabolic syndrome is insulin resistance, and its lipid signature is "high TG + low HDL + small dense LDL" — a change in the "quality" of lipoproteins, not a rise in the "quantity" of LDL, so diagnosis looks only at TG and HDL. (By comparison, the US NCEP ATP III waist-circumference cutoffs are more lenient: >102 cm for men, >88 cm for women.)

Obesity: Taiwan's Ruler Is Stricter Than the West's

Taiwan's obesity cutoff is BMI ≥ 27, not the 30 used in the West — because at the same BMI, Asians have higher body fat and higher cardiovascular risk. The waist-circumference cutoff is ≥ 90 for men, ≥ 80 for women. The calculation is basic: BMI = weight (kg) ÷ height (m)²; for example, 64 ÷ 1.58² = 25.7, which falls into overweight (<27, not yet obese) — interpreting this 25.7 correctly is a classic test point.

Lipid-Lowering Drugs: Follow the Cholesterol Pathway

Grapefruit juice is a classic minor test point. Statins split into two camps: the "clean camp" not metabolized via CYP3A4 — pravastatin, rosuvastatin, fluvastatin, pitavastatin — is unaffected by grapefruit juice; those metabolized via CYP3A4 — lovastatin, simvastatin, atorvastatin — have their blood concentration raised by grapefruit juice, increasing muscle toxicity. Memory hook: prava/rosuva are clean; lova/simva/atorva fear grapefruit; for patients on multiple medications (such as after a kidney transplant), pravastatin is preferred.

PCSK9: A Player You Have to Think About Backwards

Fat Is More Than Storage: Leptin and Adiponectin

Remember the adipokines in obesity in one sentence: leptin is abundant but useless; adiponectin is scarce but precious.

Treatment: Thresholds for Surgery and Medication

For the indications for weight-loss (metabolic) surgery, the mainstream exam answer still follows the NIH 1991 version: BMI ≥ 40, or BMI ≥ 35 with a comorbidity (diabetes, OSA, etc.). It significantly lowers mortality and can induce remission of type 2 diabetes (partly through an incretin mechanism, not simply from weight loss); the procedures include Roux-en-Y gastric bypass and sleeve gastrectomy. (From the 2026 perspective, the 2022 ASMBS/IFSO updated guidelines have already relaxed this to BMI ≥ 35 regardless of comorbidity, or 30–34.9 with a metabolic disease, and lowered it further to BMI ≥ 27.5 for consideration in Asian populations.)

Finally, two commonly tested metabolic abnormalities. The physiological changes in anorexia nervosa are: hypotension, bradycardia, hypoglycemia, but cortisol is instead elevated (chronic stress); sex hormones and leptin fall, causing amenorrhea; the gut is dominated by constipation (slow motility, diarrhea is uncommon) — "elevated cortisol" and "constipation" are two frequently tested directions. Separately, in older men, higher testosterone is associated with lower diabetes risk, while low testosterone is associated with metabolic syndrome and insulin resistance.

Back to those three emergency department beds. If you have read all the way to here, you will find that their stories actually converge on the same throughline: the adrenal gland, the thyroid, the islets, the pituitary, fat tissue — all these silent glands operate on the same grammar of "secretion → negative feedback → receptor action." Once you understand the grammar, the potassium in DKA, the lactation in Sheehan syndrome, and the reversed logic of PCSK9 stop being scattered fragments of memory and become the gestures of the same conductor left behind in different movements. Act I ends here, having brought this conductor onto the stage.

Making sense of this patient requires returning to the principle Act I hammered home again and again: every endocrine disease is the story of some feedback axis being interrupted. The calcium–phosphate axis has four leading characters — PTH, active vitamin D, calcitonin, and the increasingly implicated FGF-23. Each pulls on serum calcium and phosphate in its own direction, and a disease's biochemical fingerprint is simply the mark left behind once this tug-of-war falls out of balance.

First, Put All Four Hands on the Rope

Primary Hyperparathyroidism: The Triad Fingerprint of High Calcium, Low Phosphate, High Chloride

The woman from the opening vignette is the textbook face of primary hyperparathyroidism (PHPT). The most common cause is a single parathyroid adenoma (roughly 80%); hyperplasia and carcinoma are rare. The gland stops taking orders from serum calcium and secretes PTH on its own initiative — bone gets resorbed, the kidney clings to calcium for dear life, and phosphate is driven into the urine. Stack these three outcomes together and you get the biochemical triad that the exam always asks about.

Distinguishing PHPT from its look-alikes is exactly where the licensing exam loves to lay its ambush. Hypercalcemia is one of the most common findings in inpatients, but the outpatient culprit and the inpatient culprit differ — outpatient hypercalcemia is usually primary hyperparathyroidism; inpatient hypercalcemia is usually malignancy. Malignancy-associated hypercalcemia is mediated by PTHrP, and in that setting true PTH is actually suppressed (↓) — the exact mirror of PHPT's "inappropriately elevated PTH," and the cleanest point of distinction.

There is also a benign trap that mimics PHPT closely: familial hypocalciuric hypercalcemia (FHH). It arises from an inactivating mutation of CaSR (the calcium-sensing receptor) and presents with hypercalcemia and a PTH that is normal or mildly elevated — practically PHPT's twin. The key that cracks it is urinary calcium: because the kidney in FHH clings to calcium for dear life, urinary calcium runs low (urine Ca/Cr clearance ratio < 0.01), whereas PHPT's urinary calcium usually runs high. FHH is benign and needs no surgery; removing the parathyroid glands by mistake only leaves the patient with a needless scar.

As for the classification the exam most loves to test in CKD patients, it strings together into a single timeline:

• Primary: the gland itself is diseased → high Ca, low P, PTH↑.
• Secondary: CKD (high phosphate, low active vitamin D, low calcium) or vitamin D deficiency forces all four glands into compensatory hyperplasia → usually low/normal Ca, high P, PTH↑.
• Tertiary: after prolonged secondary disease, the glands become "addicted" and turn autonomous → serum calcium flips from low/normal to high, and PTH stays stubbornly elevated (common after long-term dialysis or renal transplantation).

The classic clinical mnemonic is "Stones, Bones, Groans, and psychiatric Overtones": renal stones and polyuria (calcium-induced nephrogenic diabetes insipidus); bone pain and osteitis fibrosa cystica (brown tumors); nausea, constipation, peptic ulcers, even pancreatitis; and fatigue, confusion, depression. There is one directional distinction here worth circling in red.

Hypercalcemic Emergency: Why Saline Comes First, and Why Thiazides Are Never an Option

When serum calcium surges past 14 mg/dL with symptoms, this is an emergency. The order of treatment is itself a chain of logic, not a list to memorize by rote:

`

① [First-line] Aggressive IV normal saline hydration → restores volume, ↑GFR → flushes calcium into the urine

② Once volume is restored, add a loop diuretic (furosemide) only for volume overload/heart failure, to inhibit loop-of-Henle Ca reabsorption

(modern guidelines no longer use loop diuretics routinely, but "no thiazides" always holds)

✗ Thiazides are forbidden (they actually "reduce" urinary calcium excretion, making calcium even higher)

③ Bisphosphonate (zoledronic acid) → treats the root cause but takes 1–3 days to work

④ Calcitonin → works within hours, but briefly (tachyphylaxis; only a bridge)

⑤ Denosumab → for refractory cases when bisphosphonates fail or renal function is poor

⑥ Glucocorticoid → for lymphoma/granulomatous disease/vitamin D excess (↓1,25D production)

⑦ Dialysis → for renal failure or life-threatening cases

`

Corrected Calcium: Do Not Be Fooled by Low Albumin

About 40% of serum calcium is bound to albumin. So when a patient's albumin is low, the measured "total calcium" drops along with it, but the truly active ionized calcium may not actually be low — this is pseudohypocalcemia. Before rushing to give calcium, correct for it first:

Corrected Ca (mg/dL) = measured Ca + 0.8 × (4 − albumin g/dL)

For example: albumin 2.5, measured calcium 8.0 — apparent hypocalcemia; corrected = 8.0 + 0.8 × (4 − 2.5) = 9.2 mg/dL, entirely normal. For conversion, remember Ca 1 mmol/L ≈ 4 mg/dL. Also, acid-base status directly affects ionized calcium: alkalosis makes calcium bind albumin more avidly → ionized calcium falls → this can trigger tetany (the mechanism behind hyperventilation-induced tetany).

Hypocalcemia: Evaluate in Order, and Think of Magnesium Before Giving Calcium

Evaluating hypocalcemia follows a fixed three-step order — do not skip ahead:

`

① Albumin → correct first, to rule out pseudohypocalcemia

② PTH → distinguish whether the problem lies in the parathyroid gland itself or downstream

③ Magnesium → low Mg both "suppresses PTH secretion" and "causes end-organ resistance"

(1,25(OH)₂D is not first-line)

`

The third step is the most commonly overlooked, yet the most commonly tested trap: when magnesium is low, giving calcium simply does not work, because low magnesium jams PTH so it can neither be secreted nor be heard by bone — you must replace magnesium first. The etiology then branches by whether PTH is high or low: a low PTH is usually a problem with the parathyroid gland itself (most common after surgery, low magnesium, autoimmune disease); a high PTH is compensation for trouble downstream (vitamin D deficiency, CKD, pseudohypoparathyroidism, hyperphosphatemia).

The ECG is also a free point: hypocalcemia → prolonged QTc (less calcium, slower repolarization, longer QT), flattened T waves; hypercalcemia → shortened QTc.

Osteoporosis: Same PTH, Opposite Outcomes Depending on How It Is Given

Finally we arrive at bone itself. Osteoporosis is diagnosed by DXA T-score:

Premenopausal women and children use the Z-score instead; if a fragility fracture of the hip or spine has already occurred, the diagnosis can be made clinically without DXA. Treatment splits into two camps with opposite mechanisms:

Patients on bisphosphonates need to be reminded: take orally on an empty stomach, with a large glass of water, and remain upright afterward (to prevent esophagitis); rare but important long-term complications are osteonecrosis of the jaw (ONJ) and atypical femoral fractures. One clinical detail is often tested backward — acute pain relief for a vertebral compression fracture relies on NSAIDs and short-term calcitonin, with vertebroplasty when necessary; antiresorptive agents are for "preventing future fractures," not acute pain control.

Amenorrhea: Test for Pregnancy First, Then Branch the Axis

This is an ironclad rule of gynecologic endocrinology — for any woman of reproductive age with amenorrhea, the first step is always a pregnancy test (β-hCG), which takes priority over any hormone panel. Only once pregnancy is excluded do you branch into primary versus secondary.

The reasoning chain for secondary amenorrhea flows cleanly: ① test for pregnancy → ② check TSH and prolactin (rule out the cheap, treatable causes — hypothyroidism and hyperprolactinemia — first) → ③ look at whether FSH is high or low (high indicates ovarian failure, low indicates a hypothalamic/pituitary problem) → ④ the progestin challenge test: if withdrawal bleeding follows administration of P4, it indicates the body has estrogen and has an outflow tract, most often anovulation (as in PCOS); no bleeding indicates estrogen deficiency or anatomic obstruction.

Nail this down for the exam: secondary amenorrhea is defined at 3 months (not 2 months); primary amenorrhea is defined at age 15.

The Same Estrogen, Two Faces: The Only Positive Feedback in the Entire Cycle

The menstrual cycle is a set of precision gears: menstrual phase → follicular phase (proliferative phase) → ovulation → luteal phase (secretory phase).

Behind these gears lies the two-cell, two-gonadotropin theory — a division of labor between two cell types and two gonadotropins:

In one line: LH runs the theca cell (supplying the raw material, androgens); FSH runs the granulosa cell (processing it into E2). Three more parts to remember: GnRH is secreted by the hypothalamus in a pulsatile fashion and drives both FSH and LH (not LH alone), while giving a GnRH agonist continuously (non-pulsatile) instead suppresses the gonads — this is exactly the pharmacologic basis for treating uterine fibroids and precocious puberty; hCG is a protein hormone whose receptor sits on the cell membrane (not the nucleus) and whose structure closely resembles LH; prolactin is normally kept continuously suppressed by dopamine, and in hypothyroidism a rise in TRH instead drives it up → galactorrhea plus amenorrhea.

PCOS: Unopposed Estrogen, and a Chain That Begins with Insulin

The fuller-figured 28-year-old with acne and infrequent periods is the embodiment of PCOS.

The Rotterdam diagnostic criteria require "two out of three," with other causes excluded:

Note: obesity, insulin resistance, and being overweight are "not" part of the diagnostic criteria (commonly coexist, but are not part of the criteria themselves). Treatment depends entirely on what the patient wants:

Exam point: PCOS with obesity and no desire for fertility should not go straight to ovulation-inducing drugs — weight loss comes first; for ovulation induction, letrozole is now first-line (higher live-birth rate than clomiphene).

The Four Great Syndromes of Primary Amenorrhea: Solved by One "Breast–Axillary/Pubic Hair" Axis

And what of the 16-year-old? The differential for primary amenorrhea can ride on a single axis: first check whether the breasts have developed, then whether axillary/pubic hair is present, and finally whether a uterus is present.

Müllerian Duct Anomalies: The Ovaries Are Fine, but the Blood Cannot Get Out

The paramesonephric (Müllerian) duct develops into the uterus, fallopian tubes, and upper two-thirds of the vagina; but the ovaries are not of Müllerian origin — so in these patients, ovarian function and secondary sexual characteristics are both normal, and the problem is limited to abnormal menses or cyclic abdominal pain (menstrual blood with nowhere to go). Because the mesonephric and paramesonephric ducts share a common origin, renal and urinary tract anomalies must always be screened for.

Menopause, HRT, Uterine Fibroids, and Postmenopausal Bleeding

Menopause is diagnosed by FSH > 40 mIU/mL + E2 < 30 pg/mL (persistently high FSH is the objective marker of ovarian failure). Hormone replacement follows only one logic — whether there is a uterus to protect:

A few easily confused points while we're at it: development of the external genitalia and pubic hair is driven mainly by androgens (not estrogen); HRT is contraindicated/used with caution in a history of breast or endometrial cancer, unexplained bleeding, or VTE/stroke; for vaginal dryness alone (genitourinary syndrome of menopause), low-dose local vaginal estrogen can be used on its own, with minimal systemic absorption.

Management of uterine fibroids is dictated by location (the closer to the FIGO submucosal end, the better suited to hysteroscopy):

On the pharmacologic side: GnRH agonists shrink fibroids through "continuous stimulation → downregulation → low estrogen," but are used only preoperatively for ≤ 6 months (rebound on discontinuation, plus bone loss); the newer generation of GnRH antagonists (relugolix, elagolix, with add-back therapy to prevent bone loss) can control heavy bleeding over a longer term; LNG-IUD (Mirena) and tranexamic acid control bleeding but do not shrink the fibroid; danazol is non-standard because of its pronounced virilizing side effects. Endometrial ablation targets endometrial bleeding rather than the fibroid itself, and is unsuitable for those wishing to preserve fertility.

Finally, postmenopausal bleeding (PMB) carries one ironclad rule:

The first-line workup is endometrial sampling/biopsy (or transvaginal ultrasound; postmenopausal endometrial thickness > 4 mm warrants biopsy). The most common cause is endometrial atrophy (thin and fragile); endometrial cancer accounts for roughly 10% but must always be excluded — and remember, hydrosalpinx does not cause uterine bleeding.

A few scattered but high-yield points to close out: the hair most sensitive to androgen in women is pubic hair; oogonia all arrest in fetal life at prophase I of the first meiotic division, completing meiosis only at ovulation; a 46,XX female infant with congenital adrenal hyperplasia (21-hydroxylase deficiency) shows virilized external genitalia but a normal uterus and ovaries (the internal genitalia are of Müllerian origin and unaffected by androgen); true hermaphroditism can present with an ovotestis; persistent Müllerian duct syndrome (AMH or receptor defect) leaves a male with a residual uterus/fallopian tubes.

One Chain That Decides the Mechanism: Chemical Nature → Solubility → Receptor Location

Two favorite traps are buried here: although T4 is derived from tyrosine, it is lipid-soluble and binds a "nuclear" receptor (not a membrane one); 1,25-DHCC (active vitamin D) is a sterol and also uses a nuclear receptor. Conversely, amines (epinephrine), although likewise derived from tyrosine, use a membrane receptor. Do not be misled by "derived from the same tyrosine."

The Hypothalamic–Pituitary Axis: The Anterior Lobe Manufactures, the Posterior Lobe Stores

The hypothalamus releases hormones → the pituitary anterior lobe synthesizes and secretes its own trophic hormones → target glands. Rather than memorizing this chain by brute force, it helps to see through to one regularity: the hypothalamus's releasing hormones almost always "call out by name" the anterior-lobe hormone they are meant to stimulate, so GnRH drives the gonadotropins (FSH/LH), TRH drives TSH, CRH drives ACTH, GHRH drives GH — say the name aloud and the target appears. Only three exceptions truly need separate understanding, and each has its own logic: when TRH drives TSH it also "incidentally" raises prolactin, because the two share an upstream connection — this explains why hypothyroidism is often accompanied by galactorrhea; GH is not only driven but also braked by somatostatin, making it a push-and-pull, bidirectional control; and prolactin is more peculiar still — its default state is not to be driven at all but to be continuously suppressed by dopamine — the only hormone in the entire anterior lobe whose main axis is "suppression." Remember this and it makes perfect sense why, when the pituitary stalk is compressed and dopamine can no longer get through, prolactin rises instead. Once you have worked through this "call by name plus three exceptions" logic, the correspondences below no longer need rote memorization: GnRH→FSH/LH, TRH→TSH (also raising PRL), CRH→ACTH, GHRH→GH (braked by somatostatin), dopamine→suppresses PRL.

The pituitary posterior lobe, meanwhile, synthesizes no hormones at all — it is merely a warehouse, storing and releasing two hormones already made by the hypothalamus: oxytocin (milk ejection + uterine contraction) and ADH/vasopressin (water reabsorption in the renal collecting duct).

Three frequently tested attributions to pin down: GnRH is secreted by the hypothalamus (not the anterior lobe); oxytocin/ADH are released by the posterior lobe (not the anterior lobe, and are synthesized by the hypothalamus); the suprachiasmatic nucleus (SCN) is the body's master circadian pacemaker, governing the diurnal rhythms of cortisol and melatonin.

The Adrenal Gland: From Outside In, the Deeper the Sweeter and More Sexual

The mnemonic for the three cortical zones is "Salt, Sugar, Sex" — from outside to inside (glomerulosa, fasciculata, reticularis), growing progressively more "sweet" and more "sexual":

A few details you must know cold: cortisol peaks in the early morning (synchronized with the SCN and pulsatile ACTH, not at nightfall); ACTH signals through the PKA (cAMP) pathway, not PKC; the StAR protein transports cholesterol into the inner mitochondrial membrane and is the rate-limiting step of steroidogenesis; DHEA is regulated by ACTH (not LH — LH governs the gonads); cortisol is the least likely hormone to increase bone mass (chronic excess → osteoporosis, proximal myopathy, central obesity = Cushing syndrome). The medulla is distinctive — it is directly innervated by preganglionic sympathetic neurons (ACh → nicotinic receptors), behaving like a "specialized postganglionic neuron," and secretes epinephrine (about 80%) and norepinephrine.

21-hydroxylase deficiency is the most common form of CAH, and its mechanism is an elegant diversion chain:

Primary Hyperaldosteronism (Conn Syndrome)

So its fingerprint is: hypertension + hypokalemia + metabolic alkalosis + low renin, screened for with an elevated aldosterone/renin ratio. Pheochromocytoma is often tested alongside it — likewise an "adrenal tumor plus hypertension" — but hyperaldosteronism presents as sustained hypertension plus hypokalemia, while pheochromocytoma presents as episodic hypertension plus palpitations, headache, and sweating (catecholamines).

Thyroid, Insulin, and Parathyroid Physiology: Three Reinforcements

Thyroid iodine uptake relies on the Na⁺/I⁻ symporter (NIS) on the basolateral membrane of follicular cells, a secondary active transport process that uses the Na⁺ gradient built by Na⁺/K⁺-ATPase to pump iodine into the cell against its concentration gradient. For interpretation, remember: TSH is the most sensitive marker (the earliest to change in primary hypothyroidism), while free T4 best reflects actual function (best for confirming hypothyroidism/assessing severity) — read the two together. The free form of thyroid hormone enters the cell and binds a nuclear receptor; in hypothyroidism, TRH↑ → TSH↑ plus PRL↑ → galactorrhea and amenorrhea.

Insulin secretion follows an elegant depolarization chain: blood glucose↑ → GLUT2 (a high-Km sensor on the β-cell membrane; this is the rodent model and board convention, as human β cells mainly express GLUT1) takes up glucose → glycolysis generates ATP↑ → closes ATP-sensitive K⁺ channels → the membrane depolarizes → voltage-gated Ca²⁺ channels open → intracellular Ca²⁺↑ → vesicle exocytosis → insulin is released.

Pharmacologic connection: sulfonylureas directly close this same K⁺-ATP channel, stimulating insulin secretion (hence independent of blood glucose, and capable of causing hypoglycemia). Also remember: GLUT2 is responsible for "sensing" blood glucose (β cells, liver; human β cells mainly use GLUT1); GLUT4 is the transporter insulin "recruits by translocation" (muscle, fat). Insulin's acute action (seconds) is GLUT4 translocation and activation of existing enzymes; protein synthesis occurs only hours later (it is not an acute effect); insulin is regulated directly by blood glucose, with only weak circadian rhythmicity.

The mnemonic for the parathyroid: PTH keeps calcium in and drives phosphate out. So after parathyroidectomy → serum calcium↓, serum phosphate↑ (note: one falls and one rises, not both falling), and tetany with Chvostek/Trousseau signs appears clinically.

The Gonadal Axis: Division of Labor Between Cell Types, and Gonadal Failure

The feedback details of the female cycle (E2 sustained above peak for ≥ 36 h flips to positive feedback → LH surge, ovulation about 10–12 h after the peak, the corpus luteum fixed at about 14 days) were already strung together in the previous section; one image to add: only a mature Graafian follicle has a cumulus oophorus. The male side mirrors the female side beautifully:

Why this division of labor: LH is the "interstitial-stimulating" signal, so it naturally lands on the interstitial Leydig cell to drive testosterone; FSH is the "follicle/support-stimulating" signal, so it naturally lands on the Sertoli cell to nurture sperm and secrete inhibin, which feeds back to suppress FSH (the female granulosa cell also secretes inhibin — the two sexes are perfectly symmetric). Once you understand that each signal seeks out its matching cell, LH → Leydig → testosterone, FSH → Sertoli → sperm + inhibin no longer needs rote memorization. Semen composition: seminal vesicles about 60%, prostate about 30%, Cowper's gland, with the urethra contributing the least.

Klinefelter syndrome (47,XXY): testicular failure → testosterone↓ → loss of negative feedback → LH and FSH rise (hypergonadotropic hypogonadism), presenting as tall and slender build, gynecomastia, small testes, infertility. Trap: high prolactin plus low testosterone is usually a pituitary tumor or insufficient dopamine suppression — cryptorchidism does not cause hyperprolactinemia.

Growth Hormone, Leptin, and the Stress Response

GH's mechanism is dual: hypothalamic GHRH↑/somatostatin↓ → the anterior lobe secretes GH in a pulsatile fashion → GH signals through the JAK2/STAT5 receptor → acting directly on one hand (raising blood glucose, lipolysis, anti-insulin) and, on the other, driving hepatic production of IGF-1 (somatomedin C), which mediates growth (cartilage, bone, muscle).

Exam point: GH is secreted pulsatilely, peaking during nocturnal deep sleep, so a single random GH draw has limited value; excess before epiphyseal closure → gigantism, after closure → acromegaly; acromegaly is diagnosed by failure of GH to be suppressed after an OGTT (in normal individuals, hyperglycemia suppresses GH).

On the appetite side: adipocytes secrete leptin → acting on the hypothalamic arcuate nucleus → activating POMC → α-MSH → MC4R → suppresses feeding, while simultaneously suppressing the appetite-driving NPY/AgRP; rising leptin = the signal that "energy stores are sufficient" → appetite falls (obese individuals often have leptin resistance). Its counterpart is ghrelin (secreted by the stomach, rising before meals and falling after), the only gastrointestinal hormone that stimulates appetite.

Finally, the clinical rule of the stress response: panhypopituitarism → ACTH↓ → cortisol↓ (secondary adrenal insufficiency); stress (surgery, infection, trauma) requires a stress dose of cortisol, or an adrenal crisis may follow. To distinguish secondary from primary (Addison) disease: in secondary disease, aldosterone is usually normal (propped up by RAAS) and there is no hyperpigmentation; in primary disease, ACTH↑ causes both skin hyperpigmentation and salt-wasting.

The Four Great Thyroid Cancers: First Remember Two Lines of Origin

Each diagnosis leans on its own "pillar": PTC relies on nuclear features (it does not require seeing a papillary architecture — even the follicular variant still counts as PTC); FTC relies on whether invasion is present (the cytology looks identical either way, so FNA cannot distinguish benign from malignant); MTC relies on calcitonin + amyloid; anaplastic carcinoma relies on "an elderly patient with a rapidly enlarging hard mass."

Two traps: prominent nucleoli are not a feature of PTC (PTC nuclei are pale-staining with inconspicuous nucleoli); do not confuse the surveillance markers either — thyroglobulin tracks follicular-derived cancers (PTC/FTC), while calcitonin/CEA are the markers for MTC.

MTC and MEN2 are a must-link exam point: about 25% of medullary carcinomas are hereditary, driven by a germline mutation of the RET proto-oncogene, falling into either MEN2A (MTC + pheochromocytoma + parathyroid hyperplasia) or MEN2B (MTC + pheochromocytoma + mucosal neuromas/a Marfanoid habitus, with no parathyroid disease).

Parathyroid Disease: The Three-Axis Reasoning Method

This section echoes Chapter Six, but here we work through the three axes — serum calcium × serum phosphate × PTH — all at once, through the pathologist's eye. There is only one core question: is PTH rising actively or passively? Then look at whether serum calcium is high or low.

Memory aid: primary disease is "high calcium, low phosphate" (PTH's phosphate-wasting still works); secondary disease is "low calcium, high phosphate" (the kidney has lost its ability to excrete phosphate). If a secondary-disease patient's serum calcium flips from low to high while PTH remains stubbornly elevated, this is progression to tertiary disease (the glands have become autonomous), and parathyroidectomy should be considered. In primary disease, serum chloride runs high and HCO₃⁻ runs low (a tendency toward hyperchloremic metabolic acidosis), which can distinguish it from malignancy-associated hypercalcemia — in the latter, PTH is suppressed (driven by PTHrP or bone metastases). The culprit behind hypercalcemia is usually primary hyperparathyroidism in outpatients and malignancy in inpatients, and this can be sorted out precisely by whether PTH is high or low.

Thymic Tumors: The Anterior Mediastinum's "4 T's"

Memory hook: the anterior mediastinum's "4 T's" — Thymoma, Teratoma, Thyroid, Terrible lymphoma.

Salivary Gland Tumors: The Smaller the Gland, the More Likely Malignant

The general rule to remember first: parotid tumors are mostly benign (about 75%), but sublingual gland/minor salivary gland tumors have the highest proportion of malignancy.

The key differentiating line: pleomorphic adenoma "has a chondroid component," Warthin tumor "has lymphoid stroma, no cartilage." Trap: the most common malignant salivary gland tumor is mucoepidermoid carcinoma, not SCC.

Nasal Cavity/Nasopharynx and Oral Cavity/Oropharynx: Tumors Sorted by Virus

On the oral cavity/oropharynx side, the malignant transformation risk of mucosal lesions is a frequently tested point:

Trap: erythroplakia's malignant transformation risk (~50%) is far higher than leukoplakia's (~5%) — when a question asks "which one more urgently needs a biopsy," the answer is erythroplakia.

Three Major Ocular Pathologies

Immunosuppressants: Which Station of T-Cell Activation Do They Jam

Corticosteroids: Long-Term Side Effects Ranked by Exam Frequency

Trap: long-term corticosteroids must never be stopped abruptly (risk of acute adrenal crisis); prednisolone acts on intracellular nuclear receptors (not membrane receptors).

Thyroid Drugs

Memory hook: thyroid storm favors PTU (it has the extra effect of blocking peripheral conversion); ordinary hyperthyroidism favors methimazole (once daily, lower hepatotoxicity).

Bone Metabolism Drugs: Antiresorptive vs. Anabolic

Contrast: bisphosphonates/denosumab/raloxifene/calcitonin are all antiresorptive (less bone erosion); teriparatide is an anabolic (bone-building) agent, as are abaloparatide and romosozumab — echoing the two-faced nature of PTH from Section 6.

Diabetes Drugs

Trap: GLP-1 agonists (except oral semaglutide) and insulin must be injected; oral hypoglycemics cannot be used in T1DM; both SU and meglitinides cause hypoglycemia, whereas DPP-4i/GLP-1/metformin/SGLT2i carry low hypoglycemia risk as monotherapy. Note that both GLP-1 agonists and SGLT2i have an "extra-glycemic use" test point — the former for weight loss, the latter as standard therapy for heart failure and kidney disease.

Reproductive Endocrine Drugs: Tissue Selectivity of the Three SERMs

Trap: misoprostol is a PGE1 analog (not PGF2α); mifepristone + misoprostol are used together to terminate early pregnancy. The three SERMs differ in tissue selectivity — tamoxifen is an "agonist" in the uterus (endometrial cancer risk), raloxifene has no uterine stimulation, and clomiphene antagonizes hypothalamic ER to induce ovulation.

Growth Hormone–Related Drugs: Choosing by "Level of the Lesion"

Test point: somatotropin (GH) acts on JAK/STAT receptors (not a GPCR); octreotide worsens constipation (it inhibits gut motility — it does not treat constipation).

Hematopoietic Growth Factors: Remember "Receptor = Which Signal"

Trap: the EPO receptor signals through JAK2/STAT5 (not ERK/MAPK); TPO agonists act on the TPO receptor — do not mistake it for the G-CSF receptor.

Other Important Endocrine Drugs

From Act I's thyroid, diabetes, pituitary, and lipids, to Act II's calcium-phosphate bone metabolism, gynecologic endocrinology, general physiology, and head-and-neck pathology and pharmacology, this entire volume — Endocrinology and Metabolism — has really been saying only one thing: the body uses a single feedback network to hold every hormone in check against every other, and disease is simply the fingerprint left behind when one of those feedback loops breaks.

Compress this book into three sentences. First, when you see calcium and phosphate, think "four hands locked in a tug-of-war" — PTH and vitamin D both raise calcium, but they pull phosphate in opposite directions, so phosphate is the second clue that cracks the question; the "high calcium, low phosphate, high chloride" of primary hyperparathyroidism, the "suppressed PTH" of malignancy-associated hypercalcemia, and the "low urinary calcium" of FHH are all different outcomes of this same tug-of-war. Second, when you see a head-and-neck tumor, think "two lines of origin" — follicular epithelium and C cells go their separate ways, and the nuclear features of PTC, the calcitonin and amyloid of MTC, and the three-axis reasoning for the parathyroid glands are all signatures you can name at a glance. Third, when you see any hormone or drug, think "which station the signal is stuck at" — lipid-soluble hormones travel straight into the nucleus, water-soluble ones knock on the membrane, and this single distinction decides how fast they act; immunosuppressants, growth-hormone drugs, and hematopoietic factors likewise each fall into place according to "which leg of the relay they jam."

What truly earns steady points in the exam hall was never rote memorization of these tables, but a firm grip on the causal chain behind every section: mechanism predicts presentation, presentation predicts diagnosis, diagnosis predicts treatment. Once you can face an unfamiliar set of lab values and work backward to "which feedback loop has broken," endocrinology stops being a pile of disconnected mnemonics and becomes a map you can actually read. May this map walk with you through the exam hall, and follow you into every real clinic you enter afterward.